UTAA91 injection for refractory rheumatoid arthritis
Official title: Clinical Study on the Treatment of Refractory Moderate - to - Severe Active Rheumatoid Arthritis With UTAA91 Injection
Run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · NCT07001956 · Data updated 2026-11-12
This trial will test whether injecting UTAA91 is safe for adults with moderate-to-severe rheumatoid arthritis that has not responded to standard treatments.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 24 (estimated) |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Status | Recruiting |
| Started | May 30, 2025 |
| Main results expected | December 2027 |
| Study ends | June 2040 |
| Registry record updated | July 18, 2025 |
| Trial ID | NCT07001956 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with moderate-to-severe active rheumatoid arthritis unresponsive to standard treatments, adequate liver/kidney/cardiopulmonary function, no severe psychiatric disorder, and able to give informed consent.
✕Probably not a fit
Patients with recent malignancy within five years, positive viral or syphilis tests, severe cardiac or unstable systemic disease, active uncontrolled infections, CNS involvement, or who are pregnant or breastfeeding are unlikely to be eligible or benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an open-label, single-arm, single-center early-phase 1 trial enrolling adults with refractory moderate-to-severe active rheumatoid arthritis. Participants will receive UTAA91 injections and be monitored primarily for safety using clinical exams, laboratory tests, and adverse event reporting. The study is investigator-initiated and conducted at Union Hospital, Tongji Medical College in Wuhan, with exclusions for recent malignancy, active infections, severe cardiac disease, and pregnancy. Secondary observations will record tolerability and any preliminary signs of clinical activity.
Why it matters
Potential benefit: If safe, UTAA91 could provide a new treatment option for patients with refractory moderate-to-severe RA who have exhausted standard therapies.
How similar studies have gone: UTAA91 appears to be an early-phase, novel intervention with limited prior clinical data specifically for this agent, although other injectable targeted therapies for refractory RA have shown mixed early promise.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged ≥18 years (inclusive of the boundary value), with no restriction on gender. * Expected survival time of at least 3 months. * Subjects with refractory moderate - to - severe active rheumatoid arthritis who have failed standard treatment or lack effective therapeutic options. * Meet the requirements for liver and kidney function, as well as cardiopulmonary function. * Free from severe psychiatric disorders. * Able to understand the trial and have signed the informed consent form. Exclusion Criteria: * A history of malignant tumors other than relapsed/refractory autoimmune diseases (R/R AID) within 5 years prior to screening. * Subjects with positive results in virus/syphilis tests. * Severe cardiac diseases or unstable systemic diseases. * Active or uncontrollable infections requiring systemic treatment within 7 days before administration; evidence of central nervous system invasion at screening. * Pregnant or breastfeeding women, female subjects planning to become pregnant within 2 years after cell infusion, or male subjects whose partners plan to become pregnant within 2 years after their cell infusion. * Subjects who have received CAR - T therapy or other gene - modified cell therapies before screening. * Subjects who participated in other clinical studies within 1 month before screening. * Other conditions deemed unsuitable for enrollment by the investigator.
Where it's running
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China Recruiting
Study contacts
- Study coordinator: Qiubai Li, MD
- Email: qiubaili@hust.edu.cn
- Phone: +8613995671635
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Heart Rate Variability and Rheumatoid Arthritis: What HRV Looks Like with RA
This study checks whether continuous HRV data from an Oura ring can reflect RA disease activity in adults with RA.
-
Discontinuing MTX or LEF in RA Patients on TNF Inhibitors
This trial tests whether stopping methotrexate or leflunomide while continuing a TNF inhibitor is not worse for disease control in adults with rheumatoid arthritis.
-
FT839 therapy for autoimmune diseases
This trial tests FT839, given alone or with rituximab, to see if it is safe and can help people with certain autoimmune diseases who have not responded to other treatments.
-
24-Hour Movement and Atherosclerotic Risk in adults with rheumatoid arthritis
This study tests how daily activity, sitting, and sleep relate to heart-related risk in adults with RA, using wearables and follow-up after a year.
-
Integrative AI profiling of chronic RA pain
This study tests whether an AI-driven multiomic and neurophysiological approach can help explain and predict persistent pain in adults with active rheumatoid arthritis.
-
Oxidative Stress and Heart Risk in People with Rheumatoid Arthritis
This study tests whether certain markers of oxidative stress in people with rheumatoid arthritis are linked to subclinical atherosclerosis and arterial stiffness, which could relate to future heart disease risk.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.